Week Of September 17, 2012: Pfizer Launches Joint Venture In China; Spectrum Sartorius Opens New Facility In Germany; And More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week Of September 17, 2012: Pfizer Launches Joint Venture In China; Spectrum Sartorius Opens New Facility In Germany; And More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Pfizer and the Chinese pharmaceutical company Zhejiang Hisun Pharmaceuticals have launched Hisun-Pfizer Pharmaceuticals, a joint venture formed between the two companies to develop, manufacture, and commercialize off-patent pharmaceutical products in China and global markets. Read More

On Sept. 12, 2012, Sartorius opened its new facility in Guxhagen, Germany, for the manufacture of bioreactors following a one-year, EUR 18-million ($23.5 million) construction project. The 100,000-ft2 complex will serve clients in the biopharmaceutical industry and provide space for a high-tech manufacturing hall and offices for around 240 employees. Read More

Xcelience opened its new 24,000-ft2 facility in Tampa, Florida, on Sept. 14, 2012. The building will be used for primary and secondary packaging, labeling, distribution, and warehouse services. This is the company’s second facility in the Tampa Bay area, and the company says it will be audited and approved for domestic as well as European clinical trials. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here